Cadence CoMET Trial

Cadence CoMET is the fourth clinical trial in the Cadence series

The CoMET trial will examine if starting a diabetes medication called metformin at the same time as the antipsychotic medication clozapine can minimise the weight gain that can occur with clozapine treatment.

Metformin is a commonly used medication for diabetes but is not approved by the Therapeutic Goods Administration (TGA) for weight loss. Previous research however, has found it to promote weight loss in people who have gained weight after clozapine treatment.

People with schizophrenia are known to have a shorter life expectancy due to diseases such as heart disease and diabetes. This is a result of many factors including obesity, poor diet, reduced physical activity and antipsychotic medications. Antipsychotic medications are an essential part of current treatment for schizophrenia and schizoaffective disorder so it is important to examine treatments to target these side effects.

Physical activity programs have been shown to be effective in improving the physical health and weight management for some people taking antipsychotic medications but not all. For this reason it is important to explore other options for improving the physical health of people taking antipsychotic medications.

This research has been initiated by the Coordinating Principal Investigator Associate Professor Dan Siskind (Metro South Addiction and Mental Health Service). The Research Manager is Andrea Baker and the Study Coordinator is Clare Gamble. They both work at the Queensland Centre for Mental Health Research (QCMHR) along with a team of research assistants who will be working on this trial.